

## DAFTAR PUSTAKA

- Alsagaff, M.Y., Mulia, E.P.B., Maghfirah, I., Luke, K., Nugraha, D., Rachmi, D.A., Septianda, I., dan A'yun, M.Q., 2021. Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, **15**: 102210. <https://linkinghub.elsevier.com/retrieve/pii/S1871402121002307>.
- Amar, J., Touront, N., Ciron, A.M., dan Pendaries, C., 2021. Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19. *The Journal of Clinical Hypertension*, **23**: 238–244. <https://onlinelibrary.wiley.com/doi/10.1111/jch.14137>.
- Baral, R., Tsampasian, V., Debski, M., Moran, B., Garg, P., Clark, A., dan Vassiliou, V.S., 2021. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. *JAMA Network Open*, **4**: e213594. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777978>.
- Bavishi, C., Whelton, P.K., Mancia, G., Corrao, G., dan Messerli, F.H., 2021. Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. *Journal of Hypertension*, **39**: 784–794. <https://journals.lww.com/10.1097/HJH.0000000000002784>.
- Bezabih, Y.M., Bezabih, A., Alamneh, E., Peterson, G.M., dan Bezabhe, W., 2021. Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. *BMC Infectious Diseases*, **21**: 527. <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06088-6>.
- Caldeira, D., Alves, M., Gouveia e Melo, R., Silvério António, P., Cunha, N., Nunes-Ferreira, A., Prada, L., Costa, J., dan Pinto, F.J., 2020. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. *IJC Heart & Vasculture*, **31**: 100627. <https://linkinghub.elsevier.com/retrieve/pii/S2352906720303250>.
- Choksi, T.T., Zhang, H., Chen, T., dan Malhotra, N., 2021. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. *American Journal of Nephrology*, **52**: 250–260. <https://www.karger.com/Article/FullText/515232>.

- Clark, C.E., McDonagh, S.T.J., McManus, R.J., dan Martin, U., 2021. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. *Journal of Human Hypertension*, **35**: 304–307. <http://www.nature.com/articles/s41371-020-00451-x>.
- Cui, J., Li, F., dan Shi, Z.-L., 2019. Origin and evolution of pathogenic coronaviruses. *Nature Reviews. Microbiology*, **17**: 181–192. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097006/>.
- Dai, X.-C., An, Z.-Y., Wang, Z.-Y., Wang, Z.-Z., dan Wang, Y.-R., 2021. Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. *Frontiers in Cardiovascular Medicine*, **8**: 609857. <https://www.frontiersin.org/articles/10.3389/fcvm.2021.609857/full>.
- DiPiro, J.T., Yee, G.C., Talbert, R.L., Matzke, G., Posey L.M., Wells, B.G., 2017, *Pharmacotherapy: A Pathophysiologic Approach*, 10<sup>th</sup> Edition, United States: McGraw-Hill.
- DPPTM Kementerian Kesehatan Republik Indonesia, 2013. *Pedoman Teknis Penemuan & Tatalaksana Hipertensi*. Jakarta: Direktorat Pengendalian Penyakit Tidak Menular, Kementerian Kesehatan Republik Indonesia.
- Genet, B., Vidal, J.-S., Cohen, A., Bouilly, C., Beunardeau, M., Marine Harlé, L., Gonçalves, A., Boudali, Y., Hernandorena, I., Bailly, H., Lenoir, H., Piccoli, M., Chahwakilian, A., Kermanach, L., de Jong, L., Duron, E., Girerd, X., dan Hanon, O., 2020. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients. *Journal of the American Medical Directors Association*, **21**: 1539–1545. <https://linkinghub.elsevier.com/retrieve/pii/S1525861020307878>.
- Hasan, S.S., Kow, C.S., Hadi, M.A., Zaidi, S.T.R., dan Merchant, H.A., 2020. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. *American Journal of Cardiovascular Drugs*, **20**: 571–590. <https://link.springer.com/10.1007/s40256-020-00439-5>.
- Higashi, Y., Kihara, Y., dan Noma, K., 2012. Endothelial dysfunction and hypertension in aging. *Hypertension Research*, **35**: 1039–1047. <https://www.nature.com/articles/hr2012138>.
- Huang, S., Wang, J., Liu, F., Liu, J., Cao, G., Yang, C., Liu, W., Tu, C., Zhu, M., dan Xiong, B., 2020. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study.

*Hypertension Research*, **43**: 824–831.  
<http://www.nature.com/articles/s41440-020-0485-2>.

Ji, Y.L., Wu, Y., Qiu, Z., Ming, H., Zhang, Y., Zhang, A.N., Leng, Y., dan Xia, Z.Y., 2021. The Pathogenesis and Treatment of COVID-19: A System Review. *Biomedical and Environmental Sciences*, **34**: 50–60.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870101/>.

Jia, N., Zhang, G., Sun, X., Wang, Y., Zhao, S., Chi, W., *et al.*, 2021. Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis. *The Journal of Clinical Hypertension*, **23**: 1651–1663.  
<https://onlinelibrary.wiley.com/doi/10.1111/jch.14329>.

Kai, H. dan Kai, M., 2020. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. *Hypertension Research*, **43**: 648–654.  
<http://www.nature.com/articles/s41440-020-0455-8>.

Kaur, U., Chakrabarti, S.S., dan Patel, T.K., 2021. Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. *Therapeutic Advances in Drug Safety*, **12**: 204209862110113.  
<http://journals.sagepub.com/doi/10.1177/20420986211011345>.

Kementerian Kesehatan Republik Indonesia, 2020. *Pedoman Pencegahan dan Pengendalian Coronavirus Disease (Covid-19)*, revisi ke-5, Jakarta : Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia, 2021a. *Infeksi Emerging Kementerian Kesehatan*. <https://infeksiemerging.kemkes.go.id/> diakses pada 22 September 2021 pukul 21.00 WIB.

Kementerian Kesehatan Republik Indonesia, 2021b. *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/5671/2021 Tentang Manajemen Klinis Tata Laksana Corona Virus Disease 2019 (COVID-19) Di Fasilitas Pelayanan Kesehatan*, <https://covid19.go.id/storage/app/media/Regulasi/2021/Agustus/kmk-no-hk0107-menkes-5671-2021-ttg-manajemen-klinis-tata-laksana-covid-19-di-fasilitas-pelayanan-kesehatan-signed-1.pdf> diakses pada 14 Oktober 2021 pukul 20.00 WIB.

Kow, C.S., Ming, L.C., dan Hasan, S.S., 2021a. Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. *Hypertension*

*Research*, **44**: 1042–1045. <https://www.nature.com/articles/s41440-021-00670-w>.

Kow, C.S., Ramachandram, D.S., dan Hasan, S.S., 2021b. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. *Hypertension Research*, **45**: 360–363. <https://www.nature.com/articles/s41440-021-00786-z>.

Kurdi, A., Abutheraa, N., Akil, L., dan Godman, B., 2020. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? *Pharmacology Research & Perspectives*, **8**. <https://onlinelibrary.wiley.com/doi/10.1002/prp2.666>.

Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., dan Hsueh, P.-R., 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, **55**: 105924. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127800/>.

Lee, M.M.Y., Docherty, K.F., Sattar, N., Mehta, N., Kalra, A., Nowacki, A.S., Solomon, S.D., Vaduganathan, M., Petrie, M.C., Jhund, P.S., dan McMurray, J.J.V., 2020. Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. *European Heart Journal - Cardiovascular Pharmacotherapy*, **8**: 165–178. <https://academic.oup.com/ehjcvp/article/8/2/165/6041623>.

Lee, T., Cau, A., Cheng, M.P., Levin, A., Lee, T.C., Vinh, D.C., Lamontagne, F., Singer, J., Walley, K.R., Murthy, S., Patrick, D., Rewa, O.G., Winston, B.W., Marshall, J., Boyd, J., Tran, K., Kalil, A.C., McCulloh, R., Fowler, R., Luther, J.M., dan Russell, J.A., 2021. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. *CJC Open*, **3**: 965–975. <https://linkinghub.elsevier.com/retrieve/pii/S2589790X21000718>.

Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., Bi, Z., dan Zhou, Y., 2020. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology*, 1–8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087935/>.

Mahamat-Saleh, Y., Fiolet, T., Rebeaud, M.E., Mulot, M., Guihur, A., El Fatouhi, D., Laouali, N., Peiffer-Smadja, N., Aune, D., dan Severi, G., 2021. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies.

*BMJ Open*, **11**: e052777.  
<https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-052777>.

PDHI, 2019, *Konsensus Penatalaksanaan Hipertensi 2019*. Jakarta: Perhimpunan Dokter Hipertensi Indonesia.

PDHI, 2020. *Panduan Diagnosis dan Tatalaksana Penyakit Kardiovaskular Pada Pandemi COVID-19*, Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.

Peng, M., He, J., Xue, Y., Yang, X., Liu, S., dan Gong, Z., 2021. Role of Hypertension on the Severity of COVID-19: A Review. *Journal of Cardiovascular Pharmacology*, **78**: e648–e655.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562915/>.

Ren, L., Yu, S., Xu, W., Overton, J.L., Chiamvimonvat, N., dan Thai, P.N., 2021. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. *Journal of Cardiology*, **77**: 482–491.  
<https://linkinghub.elsevier.com/retrieve/pii/S0914508720303531>.

Sattar, Y., Mukuntharaj, P., Zghouzi, M., Suleiman, A.-R.M., Attique, H., Ullah, W., Sana, M.K., Zaher, N., Mehmood, M., Doshi, R.P., Panchal, A., Mir, T., Nadeem, M., Ali, O.E., Mohamed, M., Bagur, R., Elgendy, I.Y., Mamas, M.A., dan Alraies, M.C., 2021. Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population. *High Blood Pressure & Cardiovascular Prevention*, **28**: 405–416.  
<https://link.springer.com/10.1007/s40292-021-00462-w>.

Tikellis, C. dan Thomas, M.C., 2012. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *International Journal of Peptides*, **2012**: 256294.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321295/>.

Weiss, S.R. dan Leibowitz, J.L., 2011. Coronavirus Pathogenesis. *Advances in Virus Research*, **81**: 85–164.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149603/>.

Wells, B. G. *et al.*, 2016. *Pharmacotherapy Principles & Practice*, 4<sup>th</sup> edition, New York : McGraw-Hill Education.

Wu, Z. dan McGoogan, J.M., 2020. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*, **323**: 1239–1242.  
<https://doi.org/10.1001/jama.2020.2648>.

- Xia, F., Zhang, M., Cui, B., An, W., Chen, M., Yang, P., Qin, T., Zhou, X., Liao, Y., Xu, X., Liu, S., Li, K., Zhao, Q., Wang, K., Hu, G., Du, M., Chen, S., Zhang, Y., Wei, W., Xiang, M., dan Zhang, J., 2021. COVID-19 patients with hypertension are at potential risk of worsened organ injury. *Scientific Reports*, **11**: 3779. <http://www.nature.com/articles/s41598-021-83295-w>.
- Xiong, T.-Y., Huang, F.-Y., Liu, Q., Peng, Y., Xu, Y.-N., Wei, J.-F., Li, N., Bai, B., Li, J.-H., Prendergast, B., Li, W.-M., dan Chen, M., 2020. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. *Annals of Medicine*, **52**: 361–366. <https://www.tandfonline.com/doi/full/10.1080/07853890.2020.1802059>.
- Xu, J., Teng, Y., Shang, L., Gu, X., Fan, G., Chen, Y., Tian, R., Zhang, S., dan Cao, B., 2021. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **72**: e901–e913. <https://academic.oup.com/cid/article/72/11/e901/5932274>.
- Yang, Q., Zhou, Y., Wang, X., Gao, S., Xiao, Y., Zhang, W., Hu, Y., dan Wang, Y., 2020. Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score–matching analysis. *Respiratory Research*, **21**: 172. <https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01435-8>.
- Zeng, X., Rathinasabapathy, A., Liu, D., Zha, L., Liu, X., Tang, Y., Li, F., Lin, W., Yu, Z., dan Chen, H., 2021. Association of cardiac injury with hypertension in hospitalized patients with COVID-19 in China. *Scientific Reports*, **11**: 22389. <https://www.nature.com/articles/s41598-021-01796-0>.
- Zhang, G., Wu, Y., Xu, R., dan Du, X., 2021. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis. *Journal of Medical Virology*, **93**: 2287–2300. <https://onlinelibrary.wiley.com/doi/10.1002/jmv.26695>.
- Zhang, L.-K., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W.-J., Wu, Y., Li, S., Zhang, Y.,-L., Hao, Z.-N., Chen, H., Jin, R., Liu, W., Li, H., Peng, K., dan Xiao, G., 2020. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. *Cell Discovery*, **6**: 96. <https://www.nature.com/articles/s41421-020-00235-0>.